ImageneBio News and Activities

ImageneBio is a company listed under the stock ticker IMA (US).

Acquisition, funding and merger involving ImageneBio.

• ImageneBio is now listed under ticker IMA. (posted on July 25 2025).
• Ikena Oncology will change its company name to ImageneBio. (posted on July 24 2025).
• Inmagene Biopharmaceuticals and ImageneBio have merged  (posted on July 24 2025)..

View the org chart displaying its 18 main executives

Most searched biographies at ImageneBio

• Kristin Yarema, Chief Executive Officer and Interim Chief Financia...
• Joseph Slattery, Director
• David Bonita, Director

Popular executive movements at ImageneBio

• Benjamin Porter-Brown will join the company as Chief Medical Officer on Feb. 16, 2026  (posted on February 12 2026).
• Kristin Yarema who was Chief Executive Officer, becomes Chief Executive Officer and Interim Chief Financial Officer  (posted on October 23 2025).
• Jotin Marango, Chief Financial Officer, has left the company  (posted on October 23 2025).

Create your alert
to follow the executive moves at ImageneBio.

ImageneBio has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by ImageneBio

• Ikena Oncology to Participate in the William Blair Biotech Focus Conference 2022 | Ikena Oncology
• Ikena Oncology Receives FDA Fast Track Designation for Novel TEAD Inhibitor IK-930 to Treat Unresectable NF2-Deficient Mesothelioma | Ikena Oncology
• Ikena Oncology to Participate in Spring 2022 Investor Conferences | Ikena Oncology
• Ikena Oncology Reports First Quarter 2022 Financial Results and Provides a Corporate Update | Ikena Oncology
• Ikena Oncology and Vall d’Hebron Institute of Oncology Announce Research & Development Collaboration | Ikena Oncology
• Ikena Oncology to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting | Ikena Oncology
• Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual Meeting | Ikena Oncology
• Ikena Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update | Ikena Oncology
• Ikena Appoints Richard Wooster, Ph.D., to its Board of Directors | Ikena Oncology
• Ikena Oncology to Participate in Cowen 42nd Annual Health Care Conference | Ikena Oncology
• View more press releases Close

Social media about ImageneBio

• ImageneBio on Wikipedia, Google News & Yahoo Finance
• ImageneBio on LinkedIn, X (Twitter) & YouTube